News Pfizer, Arvinas join SERD club with Veppanu approval Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News FDA's ODAC delivers one loss, one win for AstraZeneca The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News AZ will invest £300m in UK, says PM Keir Starmer AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.
News Amgen, AZ will pilot FDA's real-time clinical trial plan The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
News UK study finds clue to rising cancer rates in younger people A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main driving factor.
News Lilly's M&A team strikes again with $2.3bn Ajax takeover With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.
News Lilly partners with Hims & Hers on obesity drug sales Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
